{"id":"F2015L01150","name":"Therapeutic Goods (Listing) Notice 2015 (No. 3)","slug":"therapeutic-goods-listing-notice-2015-no-3","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":129011,"registerId":"commonwealth-F2015L01150-current","compilationNumber":null,"startDate":"2026-04-03","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Therapeutic Goods (Listing) Notice 2015 (No. 3)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 20.2\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n \n\n \n\nTherapeutic Goods Act 1989\n\n \n\nTherapeutic Goods (Listing) Notice 2015 (No. 3)\n\n \n\nI, JOHN SKERRITT, National Manager of the Therapeutic Goods Administration, delegate of the Minister for Health for the purposes of subsection 9A(5) of the Therapeutic Goods Act 1989 (the Act) and acting under that provision, require the following therapeutic goods to be included in the part of the Australian Register of Therapeutic Goods (the Register) for listed goods:\n\n \n\n- preparations that contain ‘Polaprezinc’ as a therapeutically active ingredient, subject to the following condition:\n  - the preparation contains a recommended daily dose of 25 milligrams or less of zinc; and\n  - the preparation is for oral use only.\n\n\n \n\nThis Notice commences from the day after it is registered on the Federal Register of Legislative Instruments.\n\n \n\n \n\n \n\nDated this 25th day of June 2015\n\n \n\n \n\n(Signed by)\n\n \n\n \n\nJohn Skerritt\n\nDelegate of the Minister for Health\n","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-batch","completionTokens":1660},"content_quality":"ok","complexity_score":1,"scope_assessment":{"changed":false,"description":"The instrument remains precisely focused on its original purpose of authorising a specific zinc compound (Polaprezinc) for use in listed medicines with defined dosage and route-of-administration constraints. No expansion beyond this specific technical approval."},"complexity_factors":["Single operative provision containing a straightforward inclusion requirement","Only two simple conditions (daily dose limit of 25mg zinc and oral administration only)","No cross-references to other legislative provisions beyond the empowering subsection","No defined terms, schedules, or interpretive provisions","Extremely concise instrument with minimal conditional logic"],"plain_english_summary":"This notice authorises Polaprezinc (a zinc compound) to be used as an active ingredient in listed (lower‑risk) complementary medicines on the ARTG, limited to oral products and a recommended daily zinc dose of 25 mg or less. It affects supplement manufacturers/importers and consumers by expanding safe formulation options for oral zinc supplements while keeping dose limits to protect safety."}},"importantCases":[],"_links":{"self":"/api/acts/therapeutic-goods-listing-notice-2015-no-3","history":"/api/acts/therapeutic-goods-listing-notice-2015-no-3/history","analysis":"/api/acts/therapeutic-goods-listing-notice-2015-no-3/analysis","conflicts":"/api/acts/therapeutic-goods-listing-notice-2015-no-3/conflicts","importantCases":"/api/acts/therapeutic-goods-listing-notice-2015-no-3/important-cases","documents":"/api/acts/therapeutic-goods-listing-notice-2015-no-3/documents"}}